Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,474 total articles
Abbott has moved up from its May lows but remains attractive for investors focused on steady cash flow, margin resilience, and secular growth in diagnostics and chronic care. The balance sheet is healthy, free cash flow is meaningful at $7.82B, and the dividend yields roughly 2.25%. Valuation is no longer a deep value, but at a market cap of about …
Northeast Community Bancorp (NECB) looks like an attractive buy today: market cap ~$370M, P/E ~8.5 and P/B ~1.04, a raised quarterly dividend ($0.25) that lifts the yield to roughly 3.7%-3.8%, and a construction loan pipeline with $819M in unfunded commitments. Asset quality is excellent (zero non-performing loans reported) and capital is healthy. …
Diageo ($DEO) is delivering early signs of a recovery: brand-level wins in China, a clear premiumization runway, and technicals clustering around support. At a market cap near $50.9B and a current price of $91.16, the stock looks poised for a mid-term rebound if sales stabilize and margin actions continue. This article lays out a concrete trade pla…
Meta is trading at a lower multiple while free cash flow and profitability remain strong. AI-driven product improvements are already boosting engagement and ad yields. This trade targets a rally as markets re-price Meta for durable AI monetization, while respecting legal and regulatory tail risks.
Runway Growth Finance (RWAY) is a closed-end business development company offering senior secured loans to growth-stage tech and life sciences. The stock trades at roughly a 45% discount to estimated NAV, yields ~20% from a $0.33 quarterly distribution, and benefits from a recently completed SWK acquisition that expanded assets to $1.2B. We present…
Boise Cascade (BCC) is a cash-generative wood products and building materials distributor trading at a modest multiple, with an EV/EBITDA of 9.2, market cap of roughly $2.8B and free cash flow of $103M. The balance sheet is healthy, and housing-related end markets show improving fundamentals. We lay out a mid-term (45 trading days) long trade with …
Mercury General's recent underwriting recovery and strong cash generation compress downside risk while leaving room for share price re-rating. The company trades at a single-digit P/E and exhibits robust ROE and free cash flow - a classic value setup with definable catalysts and manageable balance-sheet risk.
Mainstreet Equity trades at an attractive entry after a period of sideways action. The company runs a portfolio of cash-generating businesses, and at $22.50 the risk/reward favors a long position: entry $22.50, stop $19.00, target $30.00 over the next 180 trading days.
H&R Block reported steady fiscal 2026 results (revenue $3.95B, adjusted net income $688M), repurchased nearly 8% of shares and raised its quarterly dividend to $0.46. With free cash flow of $760.9M, an EV/EBITDA of 6.75 and a P/E around 8.5-9x, the stock looks attractive for a mid-term long trade. I outline an entry at $50.95, stop at $46.00 and ta…
Micron is a fundamentally strong, cash-rich semiconductor that still trades with wide intraday swings and heavy options interest. That combination creates repeated opportunities to sell premium and establish defined-risk directional spreads. This trade uses a bullish 45-day call-spread plus a repeatable short-call selling plan to harvest theta whil…
SpaceX is one of the rare private companies that combines durable commercial launch demand, growing recurring revenue from Starlink, and strategic government contracts. Fundamentals are strong, but a near-term trade should respect valuation: this is a buy-on-dip setup rather than a buy-and-forget. I recommend a disciplined entry at $75.00 with a ti…
Palantir's Q2 momentum (reported ~93% revenue growth) and exceptional operating leverage make a compelling case that the market is underestimating the durability of its growth and margin profile. The stock is richly valued on headline multiples today, but near-term catalysts tied to sovereign AI adoption, expanding commercial footprints, and sustai…
Globus Medical has delivered seven consecutive quarters of margin expansion while continuing to grow revenue and generate strong free cash flow. The stock trades at $86.42 with a market cap near $11.6B and appears to underprice improving fundamentals and recent M&A. This is a long trade idea sized for disciplined risk seekers, with a clear entry, s…
<p>Capcom and Square Enix both sit on storied franchises and deep IP, but for investors the distinction between a great game company and a great investment can be material. This trade pairs a long position in Capcom with a short in Square Enix to capture valuation divergence, monetization strength, and differing capital allocation profiles. The pai…
HNI (HNI) is an actionable buy around $47.50. The completed exchange offer for Steelcase notes and expected closing of the Steelcase acquisition combined with improving workplace demand, recent product rollouts, and an attractive enterprise multiple create a clear path to mid-term upside. Set a disciplined stop and target to manage execution risk.
Adobe's core franchises remain cash-generative and resilient. With trailing P/E ~14.5, free cash flow of $10.28B and AI-first ARR beginning to matter, the stock looks attractive for a tactical swing position. This trade outlines an entry, stop and target across short, mid and longer horizons with explicit risk controls.
Zeta Global has delivered measurable AI lift and high-growth signals, but the stock already trades at rich multiples versus its cash-flow profile. We downgrade to a tactical short: entry $28.23, target $18.50, stop $33.00, mid-term (45 trading days).
Quantinuum’s trapped-ion approach has technical advantages that matter for fault-tolerant quantum work. With expanding software, cloud partnerships and early commercial use-cases, the risk/reward favors a directional long for patient traders willing to accept high volatility. Entry $6.50, target $12.00, stop $4.75; horizon: long term (180 trading d…
<p>Playtika's operational signals and cash-generation metrics suggest the business is stabilizing, yet the market cap and price action imply a much darker outlook. With enterprise value under $2.8B and trailing free cash flow of roughly $419M, the gap between fundamentals and valuation looks compelling for a tactical long. Below I lay out the trade…
H&R Block surged after fiscal 2026 results and an aggressive capital return program. Fundamentals and valuation metrics still favor an upside-first trade, but watch buyback accounting, cyclical tax seasonality and elevated short interest. This is a tactical long with defined entry, stop and target for a mid-term swing.
Qnity Electronics is a leading supplier of specialized semiconductor and interconnect materials with recurring revenue, solid free cash flow, and a visible AI tailwind. Valuation is rich but defensible given the company's role in advanced packaging and fab materials. This trade targets a move back above the mid-$150s, with a strict stop to protect …
Blackstone mixes a durable fee-and-carry business with growing exposure to AI infrastructure financing. The stock trades on an attractive free cash flow yield, pays a meaningful dividend, and is showing constructive technicals. This trade targets company-level stability with a catalyst path tied to AI securitizations and private credit growth.
Tamboran’s move from pure exploration to producing operator in the Beetaloo Basin materially lowers appraisal risk and creates a funded pathway to accelerate drilling. The stock is trading on momentum with a $1.30B market cap and improving technicals. This trade idea outlines a long position with clear entry, stop and target, plus catalysts and the…
TORM plc (TRMD) is trading near $30 with a 7.9% yield, low valuation (PE ~8.8) and bullish technicals. With earnings approaching, the stock offers an asymmetric setup: a dividend buffer, supportive momentum, and potential upside back to the 52-week high. We outline a mid-term (45 trading days) trade with precise entry, stop and target levels and a …
Zai Lab is a beaten biotech with a $2.9B market cap that still generates growing product revenue in China and carries asymmetric upside from zocilurtatug pelitecan (zoci) after a high-profile DLL3 collaboration. Balance-sheet pressure and prior Phase 3 disappointment argue for a measured, risk-aware long: enter at $25.50, stop $21.00, target $34.00…
